Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination

Expert Review of Vaccines

Volumn 5, Issue 2, 2006, Pages 233-247

  Liu, Gentao ^b   Black, Keith L ^a   Yu, John S ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy; Dendritic cells; Drug resistance; Glioma; Tumor associated antigen

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CANCER VACCINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DENDRITIC CELL VACCINE; DOXORUBICIN; EPHRIN RECEPTOR A2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIPODOPHYLLOTOXIN; EPITOPE; FLOXURIDINE; FLUOROURACIL; INTERFERON; INTERLEUKIN 2; MELANOMA ANTIGEN 1; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PLATINUM DERIVATIVE; SURVIVIN; TAMOXIFEN; TEMOZOLOMIDE; THYMIDYLATE SYNTHASE; TOPOTECAN; TRASTUZUMAB; TUMOR ANTIGEN; TYROSINASE RELATED PROTEIN 2; VINCA ALKALOID;

ABSENCE OF SIDE EFFECTS; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SENSITIZATION; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CARCINOMA; HUMAN; LYMPHOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY; VACCINATION; DENDRITIC CELL; DOSE RESPONSE; IMMUNOLOGY; TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GLIOMA; HUMANS;

EID: 33746688570     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.5.2.233     Document Type: Review

References (126)

1. Bredel M, Zentner J. Brain-tumour drug resistance: the bare essentials. Lancet Oncol. 3(7), 397-406 (2002). Excellent review on the mechanism of brain tumor drug resistance.
2. Wakahara Y, Nawa A, Okamoto T et al. Combination effect of anti-Fas antibody and chemotherapeutic drugs in ovarian cancer cells in vitro. Oncology 54(1), 48-54 (1997).
3. Shtil AA, Turner JG, Durfee J, Dalton WS, Yu H. Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: the role of cytotoxic T lymphocytes. Blood 93(6), 1831-1837 (1999).
4. Melguizo C, Prados J, Marchal JA et al. Modulation of HLA class I expression in multidrug-resistant human rhabdomyosarcoma cells. Neoplasma 50(2), 91-96 (2003).
5. Fisk B, Ioannides CG. Increased sensitivity of adriamycin-selected tumor lines to CTLmediated lysis results in enhanced drug sensitivity. Cancer Res. 58(21), 4790-4793 (1998).
6. Pich A, Rancourt C. A role for intracellular immunization in chemosensitization of tumor cells? Gene Ther. 6(7), 1202-1209 (1999).
7. Liu G, Akasaki Y, Khong HT et al. Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene 24(33), 5226-5234 (2005). First study to provide solid data on the mechanism of sensitization of malignant glioma to chemotherapy through dendritic cell (DC) vaccination.
8. Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin. Cancer Res. 10(16), 5316-5326 (2004). Provides dramatic evidence of clinical synergy between DC vaccination and chemotherapy in de novo glioblastoma multiforme (GBM) patients.
9. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4, 321-327 (1998).
10. Wang RFRSA. Human tumor antigens for cancer vaccine development. Immunol. Rev. 170, 85-100 (1999).
11. Chi DD, Merchant RE, Rand R et al. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am. J. Pathol. 150(6), 2143-2152 (1997).
12. Liu G, Khong HT, Wheeler CJ, Yu JS, Black KL, Ying H. Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma. J. Immunother. 26(4), 301-312 (2003).
13. Chu W, Pak BJ, Bani MR et al. Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications. Oncogene 19(3), 395-402 (2000).
14. Pak BJ, Chu W, Lu SJ, Kerbel RS, Ben-David Y. Lineage-specific mechanism of drug and radiation resistance in melanoma mediated by tyrosinase-related protein 2. Cancer Metastasis Rev. 20(1-2), 27-32 (2001).
15. Nishioka E, Funasaka Y, Kondoh H, Chakraborty AK, Mishima Y, Ichihashi M. Expression of tyrosinase, TRP-1 and TRP-2 in ultraviolet-irradiated human melanomas and melanocytes: TRP-2 protects melanoma cells from ultraviolet B induced apoptosis. Melanoma Res. 9(5), 433-443 (1999).
16. Fang D, Kute T, Setaluri V. Regulation of tyrosinase-related protein-2 (TYRP2) in human melanocytes: relationship to growth and morphology. Pigment Cell Res. 14(2), 132-139 (2001).
17. Pak BJ, Lee J, Thai BL et al. Radiation resistance of human melanoma analysed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomerase. Oncogene 23(1), 30-38 (2004).
18. Duan Z, Duan Y, Lamendola DE et al. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin. Cancer Res. 9(7), 2778-2785 (2003).
19. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319(6050), 226-230 (1986).
20. Berchuck A, Kamel A, Whitaker R et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50(13), 4087-4091 (1990).
21. Gusterson BA, Gelber RD, Goldhirsch A et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J. Clin. Oncol. 10(7), 1049-1056 (1992).
22. Felip E, Del Campo JM, Rubio D, Vidal MT, Colomer R, Bermejo B. Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer 75(8), 2147-2152 (1995).
23. Vickers PJ, Dickson RB, Shoemaker R, Cowan KH. A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol. Endocrinol. 2(10), 886-892 (1988).
24. Barnes MN, Deshane JS, Siegal GP, Alvarez RD, Curiel DT. Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity. Clin. Cancer Res. 2(7), 1089-1095 (1996).
25. Paik S. Clinical significance of erbB-2 (HER-2/neu) protein. Cancer Invest. 10(6), 575-579 (1992).
26. Hancock MC, Langton BC, Chan T et al. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res. 51(17), 4575-4580 (1991).
27. Pusztai L, Esteva FJ, Cristofanilli M, Hung MC, Hortobagyi GN. Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer. Cancer. Treat. Rev. 25(5), 271-277 (1999).
28. Liu G, Ying H, Zeng G, Wheeler CJ, Black KL, Yu JS. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res. 64(14), 4980-4986 (2004).
29. Nagane M, Lin H, Cavenee WK, Huang HJ. Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications. Cancer. Lett. 162(Suppl.), S17-S21 (2001).
30. Dixit M, Yang JL, Poirier MC, Price JO, Andrews PA, Arteaga CL. Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. J. Natl Cancer Inst. 89(5), 365-373 (1997).
31. Krishnan S, Rao RD, James CD, Sarkaria JN. Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomas. Front Biosci. 8, e1-e13 (2003).
32. Shin DM, Donato NJ, Perez-Soler R et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. 7(5), 1204-1213 (2001).
33. Moscatello DK, Ramirez G, Wong AJ. A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res. 57(8), 1419-1424 (1997).
34. Yajima N, Yamanaka R, Mine T et al. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin. Cancer Res. 11(16), 5900-5911 (2005).
35. Abe TM, Wakabayashi Y, Nakagawa M et al. Expression of multidrug resistance protein gene in patients with glioma after chemotherapy. J. Neurooncol. 40(1), 11-18 (1998).
36. Abe TH, Taniguchi K, Yokomizo A et al. Possible involvement of multidrug-resistance-associated protein (MRP) gene expression in spontaneous drug resistance to vincristine, etoposide and adriamycin in human glioma cells. Int. J. Cancer. 58(6), 860-864 (1994).
37. Norris M, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N. Engl. J. Med. 334(4), 231-238 (1996).
38. Yamada A, Kawano K, Koga M, Matsumoto T, Itoh K. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. Cancer Res. 61(17), 6459-6466 (2001).
39. Alves PM, Faure O, Graff-Dubois S et al. EphA2 as target of anticancer immunotherapy: identification of HLA-A* 0201-restricted epitopes. Cancer Res. 63(23), 8476-8480 (2003).
40. Hatano M, Eguchi J, Tatsumi T et al. EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia 7(8), 717-722 (2005).
41. Lu M, Miller KD, Gokmen-Polar Y, Jeng MH, Kinch MS. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. Cancer Res. 63(12), 3425-3429 (2003).
42. Hatano M, Kuwashima N, Tatsumi T et al. Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. J. Transl. Med. 2(1), 40 (2004).
43. Bardot VD, Delattre JY, Vega F, Poisson M, Dutrillaux B, Luccioni C. Purine and pyrimidine metabolism in human gliomas: relation to chromosomal aberrations. Br. J. Cancer 70(2), 212-218 (1994).
44. Jenh CHG, Baskin F, Johnson LF. Thymidylate synthase gene amplification in fluorodeoxyuridine-resistant mouse cell lines. Mol. Pharmacol. 28(1), 80-85 (1985).
45. Correale P, Sabatino M, Cusi MG et al. In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restricted peptides derived from human thymidylate synthase. J. Chemother. 13(5), 519-526 (2001).
46. Fulda S, Debatin KM. Apoptosis pathways in neuroblastoma therapy. Cancer. Lett. 197(1-2), 131-135 (2003).
47. Ng CP, Bonavida B. A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance. Adv. Cancer Res. 85, 145-174 (2002).
48. Iwadate Y, Fujimoto S, Tagawa M et al. Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas. Int. J. Cancer. 69(3), 236-240 (1996).
49. Nakamura M, Konishi N, Tsunoda S et al. Retinoblastoma protein expression and MIB-1 correlate with survival of patients with malignant astrocytoma. Cancer 80(2), 242-249 (1997).
50. Vogelbaum MA, Tong JX, Perugu R, Gutmann DH, Rich KM. Overexpression of bax in human glioma cell lines. J. Neurosurg. 91(3), 483-489 (1999).
51. Pourquier P, Montaudon D, Huet S, Larrue A, Clary A, Robert J. Doxorubicin-induced alterations of c-myc and c-jun gene expression in rat glioblastoma cells: role of c-jun in drug resistance and cell death. Biochem. Pharmacol. 55(12), 1963-1971 (1998).
52. Bredel M, Pollack IF. The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas. Brain Res. Brain Res. Rev. 29(2-3), 232-249 (1999).
53. Naumann U, Weit S, Rieger L, Meyermann R, Weller M. p27 modulates cell cycle progression and chemosensitivity in human malignant glioma. Biochem. Biophys. Res. Commun. 261(3), 890-896 (1999).
54. Ruan S, Okcu MF, Ren JP et al. Overexpressed WAF1/Cip1 renders glioblastoma cells resistant to chemotherapy agents 1,3-bis(2-chloroethyl)-1- nitrosourea and cisplatin. Cancer Res. 58(7), 1538-1543 (1998).
55. Kondo S, Barnett GH, Hara H, Morimura T, Takeuchi J. MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene 10(10), 2001-2006 (1995).
56. Bredel MP IF, Dietrich PY. The role of protein kinase C (PKC) in the evolution and proliferation of malignant gliomas, and the application of PKC inhibition as a novel approach to anti-glioma therapy. Acta. Neurochir. 139(11), 1000-1013 (1997).
57. Jonsson G Paulie S, Grandien A. cIAP-2 block apoptotic events in bladder cancer cells. AntiCancer Res. 23(4), 3311-3316 (2003).
58. Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 61(3), 869-872 (2001).
59. Gordan JD, Vonderheide RH. Universal tumor antigens as targets for immunotherapy. Cytotherapy 4(4), 317-327 (2002).
60. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tokuda M. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int. J. Oncol. 21(2), 315-320 (2002).
61. Takai N, Miyazaki T, Nishida M, Nasu K, Miyakawa I. Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma. Cancer. Lett. 184(1), 105-116 (2002).
62. Ikehara M, Oshita F, Kameda Y et al. Expression of survivin correlated with vessel invasion is a marker of poor prognosis in small adenocarcinoma of the lung. Oncol. Rep. 9(4), 835-838 (2002).
63. Ikeguchi M, Kaibara N. Survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Br. J. Cancer 87(8), 883-887 (2002).
64. Grabowski P, Kuhnel T, Muhr-Wilkenshoff F et al. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br. J. Cancer 88(1), 115-119 (2003).
65. Nakayama K, Kamihira S. Survivin an important determinant for prognosis in adult T-cell leukemia: a novel biomarker in practical hemato-oncology. Leuk. Lymphoma 43(12), 2249-2255 (2002).
66. Cohen C, Lohmann CM, Cotsonis G, Lawson D, Santoianni R. Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Mod. Pathol. 16(6), 574-583 (2003).
67. Chakravarti A, Noll E, Black PM et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J. Clin. Oncol. 20(4), 1063-1068 (2002).
68. Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 61(16), 5964-5968 (2001).
69. Idenoue S, Hirohashi Y, Torigoe T et al. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin. Cancer Res. 11(4), 1474-1482 (2005).
70. Holladay FP, Lopez G, De M, Morantz RA, Wood GW. Generation of cytotoxic immune responses against a rat glioma by in vivo priming and secondary in vitro stimulation with tumor cells. Neurosurgery 30(4), 499-504; discussion 504-495 (1992).
71. Dermime S, Armstrong A, Hawkins RE, Stern PL. Cancer vaccines and immunotherapy. Br. Med. Bull. 62, 149-162 (2002).
72. Kikuchi T, Akasaki Y, Abe T, Ohno T. Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model. Cancer Immunol. Immunother. 51(8), 424-430 (2002).
73. Zou JP, Morford LA, Chougnet C et al. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J. Immunol. 162(8), 4882-4892 (1999).
74. Yang T, Witham TF, Villa L et al. Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas. Cancer Res. 62(9), 2583-2591 (2002).
75. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392(6673), 245-252 (1998).
76. Thurner B, Roder C, Dieckmann D et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J. Immunol. Methods 223(1), 1-15 (1999).
77. Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 2(1), 52-58 (1996).
78. Kugler A, Stuhler G, Walden P et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nature Med. 6(3), 332-336 (2000).
79. Nestle FO Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med. 4(3), 328-332 (1998).
80. Tjoa BA, Simmons SJ, Bowes VA et al. Evaluation of Phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36(1), 39-44 (1998).
81. Siesjo P, Visse E, Sjogren HO. Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-γ treatment. J. Immunother. Emphasis Tumor Immunol. 19(5), 334-345 (1996).
82. Banchereau J, Palucka AK, Dhodapkar M et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61(17), 6451-6458 (2001).
83. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med. 1(12), 1297-1302 (1995).
84. Liau LM, Black KL, Prins RM et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J. Neurosurg. 90(6), 1115-1124 (1999).
85. Yu JS, Wheeler CJ, Zeltzer PM et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 61(3), 842-847 (2001). The first glioma DC vaccine clinical trial, demonstrating safety, induction of T-cell killing and T-cell infiltration into tumors and a trend towards modestly enhanced survival.
86. Celluzzi CM, Falo LD Jr. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J. Immunol. 160(7), 3081-3085 (1998).
87. Albert ML, Pearce SF, Francisco LM et al. Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188(7), 1359-1368 (1998).
88. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392(6671), 86-89 (1998).
89. Ehtesham M, Kabos P, Gutierrez MA, Samoto K, Black KL, Yu JS. Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats. J. Immunother. 26(2), 107-116 (2003).
90. Akasaki Y, Kikuchi T, Homma S, Abe T, Kofe D, Ohno T. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J. Immunother. 24(2), 106-113 (2001).
91. Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T. Results of a Phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother. 50(7), 337-344 (2001). First glioma clinical trial to administer a fused dendritic glioma cell vaccine to patients, demonstrating safety, induction of type I cytokine responses and radiographic responses.
92. Liau LM, Prins RM, Kiertscher SM et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial Tcell responses modulated by the local central nervous system tumor microenvironment. Clin. Cancer Res. 11(15), 5515-5525 (2005).
93. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 64(14), 4973-4979 (2004). Describes a glioma DC vaccine trial suggesting markedly enhanced survival on adminstration of a lysate-pulsed DC vaccine and in vivo expansion of T cells recognizing specific tumor epitopes elicited by vaccination against uncharacterized antigens.
94. + T cells. J. Immunol. 165(4), 2287-2296 (2000).
95. Liu G, Yu JS, Zeng G et al. AIM-2: a novel tumor antigen is expressed and presented by human glioma cells. J. Immunother. 27(3), 220-226 (2004).
96. Bauman GS, Ino Y, Zlatescu MC et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int. J. Radiat. Oncol. Biol. Phys. 48(3), 825-830 (2000).
97. Cairncross JG, Ueki K, Zlatescu MC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl Cancer Inst. 90(19), 1473-1479 (1998).
98. Newsham IF, Gorse KM, Rempel SA, Luckey J, Golden JB, Bogler O. Use of horizontal ultrathin gel electrophoresis to analyze allelic deletions in chromosome band 11p15.5 in gliomas. Neuro-oncol. 2(1), 1-5 (2000).
99. Yamanaka R, Yajima N, Abe T et al. Dendritic cell-based glioma immunotherapy (Review). Int. J. Oncol. 23(1), 5-15 (2003).
100. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nature Med. 10(5), 475-480 (2004).
101. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nature Med. 10(9), 909-915 (2004).
102. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4, 321-327 (1998).
103. Lee KH, Wang E, Nielsen MB et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol. 163(11), 6292-6300 (1999).
104. Fong L, Hou Y, Rivas A et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl Acad. Sci. USA 98(15), 8809-8814 (2001).
105. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. AntiCancer Res. 20(4), 2665-2676 (2000).
106. Zeltzer PM, MB, Yu JS, Black KL. Immunotherapy of malignant brain tumors in children and adults. Child's Nerv. Syst. 15, 514-528 (1999).
107. Kruse CA, Cepeda L, Owens B, Johnson SD, Stears J, Lillehei KO. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol. Immunother. 45(2), 77-87 (1997).
108. Vaquero J, Martinez, R, de Haro J, Barbolla L, Salazar J, Santos H. Adoptive immunotherapy in glioblastoma multiforme: experience with the use of intrathecal infusions of autologous leukocytes. Arch. Neurobiol. (Madr) 50(3), 183-190 (1987).
109. Vaquero J, Martinez R, Barbolla L et al. Intrathecal injection of autologous leucocytes in glioblastoma: circulatory dynamics within the subarachnoid space and clinical results. Acta. Neurochir. (Wien) 89(1-2), 37-42 (1987).
110. Neuwelt EA, Clark K, Kirkpatrick JB, Toben H. Clinical studies of intrathecal autologous lymphocyte infusions in patients with malignant glioma: a toxicity study. Ann. Neurol. 4(4), 307-312 (1978).
111. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nature Immunol. 3(11), 999-1005 (2002).
112. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol. 3(11), 991-998 (2002). Critical review broadening the concept of immunosurveillance and introducing an immuno-editing model.
113. Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, Gilboa E. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 102(3), 964-971 (2003).
114. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 63(15), 4490-4496 (2003).
115. Gribben JG, Ryan DP, Boyajian R et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin. Cancer Res. 11(12), 4430-4436 (2005). Provides clinical evidence to demonstrate that targeting universal antigen CYP1B1 has the potential to increase chemotherapy sensitivity.
116. Kaminsky LS, Spivack SD. Cytochromes P450 and cancer. Mol. Aspects Med. 20(1-2), 70-84, 137 (1999).
117. Maecker B, Sherr DH, Vonderheide RH et al. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood 102(9), 3287-3294 (2003).
118. Antonia SJ, Mirza N, Fricke I et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin. Cancer Res. 12(3), 878-887 (2006).
119. Emens LA, Jaffee EM. Toward a breast cancer vaccine: work in progress. Oncology (Williston Park) 17(9), 1200-1211; discussion 1214, 1217-1208 (2003).
120. Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol. Immunother. 1-5 (Epub) (2005).
121. Lake RA, Robinson BW. Immunotherapy and chemotherapy - a practical partnership. Nature Rev. Cancer 5(5), 397-405 (2005). Very good review on the mechanism of chemotherapy enhancing on immunotherapy.
122. Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res. 65(18), 8059-8064 (2005).
123. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Rev. Cancer 5(4), 263-274 (2005).
124. + Tregulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J. Immunol. 173(7), 4352-4359 (2004). Demonstrates the mechanism of T-regulatory cell induction by human malignant glioma.
125. + RTEs on antitumor immunity and clinical outcome in glioblastoma multiforme patients and murine glioma hosts.
126. Cancer Immunity - Peptide Database - T cell Epitopes www.cancerimmunity. org/peptidedatabase/Tcellepitopes.html